Author:
Kashiwagi Atsunori,Kazuta Kenichi,Takinami Yuusuke,Yoshida Satoshi,Utsuno Atsushi,Nagase Itsuro
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference28 articles.
1. World Health Organization. Diabetes. Fact Sheet 312. Geneva: World Health Organization; 2011.
2. Ministry of Health, Labour, and Welfare, Japan. Results of the National Health and Nutrition Survey Japan, 2007. Tokyo: Ministry of Health, Labour, and Welfare, Japan; 2007.
3. Neumiller JJ, White JR Jr, Campbell RK. Sodium–glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70:377–85.
4. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Investig. 1994;93:397–404.
5. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:423–36.
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献